Mereo BioPharma Group plc: Form 20-F for the period ended Dec 31, 2022
Filed with the SEC on Mar 28, 2023 and accepted by EDGAR at Mar 28, 2023, 16:44 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Cost of revenue | 12 months2022-01-01 to 2022-12-31 | −GBP 936.0k | ifrs-full:CostOfSales |
| Shares outstanding | At period end2022-12-31 | 624,928,519 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001193125-23-082264. Last ingested by Listed: Oct 24, 2026, 15:15 ET. Listed shows no prices and gives no investment advice.